A randomized phase III trial of exemestane vs. anastrozole in postmenopausal women with receptor positive primary breast cancer

Study Chair
IBCSG: Dr. Manuela Rabaglio, Berne, Switzerland
NCIC CTG: Dr. Paul Goss, Boston, USA

Statistician
Judy-Anne Chapman

Lead Trial Coordinator
Holly Shaw

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
April 12, 2005

Date of Closure
December 15, 2006

Targeted Accrual
6840 patients

Final Accrual
7576 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login